FDA Approves First At-Home FluMist for Self- or Caregiver-Administration

Sep 20, 2024, 06:34 PM

The U.S. Food and Drug Administration (FDA) has approved AstraZeneca's FluMist nasal spray vaccine for self- or caregiver-administration, making it the first influenza vaccine that can be administered at home without the need for a healthcare provider. The vaccine is approved for individuals aged 2 through 49 years and aims to expand consumer access to medicines, reduce costs, and lower barriers to care. This approval represents a significant step in broadening vaccination options and enhancing public health measures. Interested individuals will complete a screening and eligibility assessment through a third-party pharmacy.